Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 20;136(10):1216-1224.
doi: 10.1097/CM9.0000000000002643. Epub 2023 Apr 6.

Incidence and survival of neuroendocrine neoplasms in China with comparison to the United States

Rongshou Zheng  1 , Hong Zhao  2 , Lan An  1 , Siwei Zhang  1 , Ru Chen  1 , Shaoming Wang  1 , Kexin Sun  1 , Hongmei Zeng  1 , Wenqiang Wei  1 , Jie He  3
Affiliations

Incidence and survival of neuroendocrine neoplasms in China with comparison to the United States

Rongshou Zheng et al. Chin Med J (Engl). .

Abstract

Background: Neuroendocrine neoplasms (NENs) are rare tumors characterized by variable biology and delayed diagnosis. However, the nationwide epidemiology of NENs has never been reported in China. We aimed to estimate the incidence and survival statistics of NENs in China, in comparison to those in the United States during the same period.

Methods: Based on the data from 246 population-based cancer registries covering 272.5 million people of China, we calculated age-specific incidence on NENs in 2017 and multiplied by corresponding national population to estimate the nationwide incidence in China. The data of 22 population-based cancer registries were used to estimate the trends of NENs incidence from 2000 to 2017 through the Joinpoint regression model. We used the cohort approach to analyze the 5-year age-standardized relative survival by sex, age group, and urban-rural area between 2008 and 2013, based on data from 176 high-quality cancer registries. We used data from the Surveillance, Epidemiology, and End Results (SEER) 18 program to estimate the comparable incidence and survival of NENs in the United States.

Results: The overall age-standardized rate (ASR) of NENs incidence was lower in China (1.14 per 100,000) than in the United States (6.26 per 100,000). The most common primary sites were lungs, pancreas, stomach, and rectum in China. The ASRs of NENs incidence increased by 9.8% and 3.6% per year in China and the United States, respectively. The overall 5-year relative survival in China (36.2%) was lower than in the United States (63.9%). The 5-year relative survival was higher for female patients than male patients, and was higher in urban areas than in rural areas.

Conclusions: The disparities in burden of NENs persist across sex, area, age group, and site in China and the United States. These findings may provide a scientific basis on prevention and control of NENs in the two countries.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Age-specific number of cases and incidence for NENs in China and the USA. NENs: Neuroendocrine neoplasms.
Figure 2
Figure 2
Trends in incidence for NENs in China and the USA, 2000–2017. NENs: Neuroendocrine neoplasms.
Figure 3
Figure 3
Relative survival of NENs by site in China and the USA. NENs: Neuroendocrine neoplasms.
Figure 4
Figure 4
Age-specific relative survival of NENs by site in China and the USA. NENs: Neuroendocrine neoplasms.
See this image and copyright information in PMC

References

    1. Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2018;68: 471–487. doi: 10.3322/caac.21493. - PubMed
    1. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: A review of neuroendocrine tumors and carcinomas. Neoplasia 2017;19: 991–1002. doi: 10.1016/j.neo.2017.09.002. - PMC - PubMed
    1. Genus TSE Bouvier C Wong KF Srirajaskanthan R Rous BA Talbot DC, et al. . Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: A UK nationwide cohort study 2013–2015. Br J Cancer 2019;121: 966–972. doi: 10.1038/s41416-019-0606-3. - PMC - PubMed
    1. Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: Are there global differences? Curr Oncol Rep 2021;23: 43. doi: 10.1007/s11912-021-01029-7. - PMC - PubMed
    1. Dasari A Shen C Halperin D Zhao B Zhou S Xu Y, et al. . Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3: 1335–1342. doi: 10.1001/jamaoncol.2017.0589. - PMC - PubMed

LinkOut - more resources